In the study conducted by Sequist et al., 8 (21.6%) of the 37 NSCLC patients harboring EGFR mutations who had tumor biopsy after acquiring drug resistance to first- or second-generation EGFR-TKI showed phenotypic changes. This evidence concerns the gene EGFR and neoplasm.